person

Alan Breier, MD

Alan Breier
as of 2026-07-01
Monitor thisAsk about this
at a glance
Roles: Principal Investigator, Author
KOL signal score 23
7 publications · 5 high-value
Cross-drug reach: 1 competitor drugs
Synthesized from structured facts only — each point cited above.

Profile

Affiliation
Indiana University
Roles
Principal Investigator, Author
KOL signal
23
Publications
7 (5 high-value)
Trial investigator
yes

Publishes on

1 drugs
Xanomeline-trospium (Cobenfy)

Trials led

5
A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia
NCT02008773Phase 2Completed
Fingolimod in Schizophrenia Patients
NCT01779700Phase 2Completed
Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects
NCT00734435Phase 2Terminated
Academic-Community EPINET (AC-EPINET)
NCT04497857—Completed
The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia
NCT01874756Phase 2Terminated

Publications & congress

7
Xanomeline and Trospium Chloride for the Treatment of Agitation Associated With Schizophrenia: PANSS-Excited Component Results From 3 Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials.
The Journal of clinical psychiatry · 2025 · high-value
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.
JAMA psychiatry · 2024 · high-value
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
Lancet (London, England) · 2024 · high-value
Evidence of trospium's ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results.
Psychopharmacology · 2023 · high-value
Antipsychotic Efficacy of KarXT (Xanomeline-Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study.
The Journal of clinical psychiatry · 2022 · high-value
Methods to address functional unblinding of raters in CNS trials.
Translational psychiatry · 2025
Muscarinic Receptor Activators as Novel Treatments for Schizophrenia.
Biological psychiatry · 2024

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on
Xanomeline-trospium (Cobenfy)
drug
PRINCIPAL_INVESTIGATOR
A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia
trial
Fingolimod in Schizophrenia Patients
trial
Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects
trial
Academic-Community EPINET (AC-EPINET)
trial
The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia
trial